Ontario elementary school teacher Sarah Zubair says she's happy with the overall support from the government, but there are key gaps in communication, vaccination and resources that need to be filled.
Video by Shibani Gokhale
The stars hit it off after a message on Instagram.
EXCLUSIVE: Screenwriter-producer-director Dre Ryan is expanding her relationship with Endeavor Content, with a two-year overall deal. Ryan is currently an an executive producer and co-creator for Apple’s limited series Lady In The Lake, and is an executive producer and supervisor for HBO Max’s series The Players Table, both of which hail from Endeavor Content. Natalie […]
Eight great options for taming those stubborn flyaways.
WINNIPEG — Manitobans 40 and over will soon be able to to get the Oxford-AstraZeneca COVID-19 vaccine. A government source has told The Canadian Press that the province is lowering the minimum age eligibility following similar moves by Ontario and Alberta. The source, who spoke on condition of anonymity, says an announcement is to be made today. Currently, the AstraZeneca vaccine in Manitoba is available to those 65 and over, and to people between 55 and 64 with certain underlying medical conditions. Health Canada has approved the vaccine for people under 55, but the National Advisory Committee on Immunization has recommended the shot only be offered to those 55 and older due to a slightly elevated risk of an extremely rare blood clot disorder. There have been just two cases of blood clots in Canada out of the more than 700-thousand doses of AstraZeneca administered so far. This report by The Canadian Press was first published April 19, 2021 The Canadian Press
In dense tropical forests in Sierra Leone, scientists have rediscovered a coffee species not seen in the wild in decades - a plant they say may help secure the future of this valuable commodity that has been imperiled by climate change. The researchers said on Monday that the species, called Coffea stenophylla, possesses greater tolerance for higher temperatures than the Arabica coffee that makes up 56% of global production and the robusta coffee that makes up 43%. The stenophylla coffee, they added, was demonstrated to have a superior flavor, similar to Arabica.
With record daily spikes all last week, the Indian capital is now the worst-hit city in the country.
Why are some COVID-19 patients finding relief from their long-term symptoms after getting the vaccine? Experts have two theories.
Gov. Ron DeSantis on Monday put a cap on one of his top legislative priorities by signing an “anti-mob” legislation into law back where it all began.
Patricia, who had been married to the singer since 1964, died in February after contracting Covid-19.
Opposing View: If Joe Biden will work with Republicans, we can expand infrastructure and economic opportunity — instead of the federal government.
Can you tell the difference between the Bengals' new uniforms and their old uniforms?
Previously made to adhere to the nuclear industry’s complex fatigue management guidelines outlined by the Nuclear Regulatory Commission, Indeavor’s Fatigue Management module is now available to the oil and gas industry! Plants and refineries can now operate efficiently while automatically adhering to the American Petroleum Institute’s (API) rules on limiting hours and days of work.
New York, New York--(Newsfile Corp. - April 19, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of EHang Holdings Limited ("EHang" or the "Company") (NASDAQ: EH) from December 12, 2019 through February 16, 2021 (the "Class Period"). The lawsuit filed ...
The 21-foot James Webb Space Telescope will be able to see across billions of light-years - capturing images of distant galaxies just after they formed.
Ford Motor Co on Monday said it would provide on-site COVID-19 vaccines to its hourly and salaried employees at manufacturing facilities in three states, stepping up efforts to keep its workers safe from the coronavirus. Ford Motor Company and the United Auto Workers (UAW) have secured contracts allowing them to provide the vaccines at the company's manufacturing facilities in Southeast Michigan, Missouri and Ohio, starting Monday, the automaker said. "COVID-19 vaccines are a major tool to help reduce the risk of infection, so we want to ensure our employees have access to vaccines," Ford's corporate medical director, Dr Francesca Litow, said.
Hugh Dancy, Laura Haddock, Nathalie Baye and Dominic West will join the cast of the new film.
Abstract: - Global Vaccine Delivery Devices Market to Reach $6. 5 Billion by 2027. - Amid the COVID-19 crisis, the global market for Vaccine Delivery Devices estimated at US$4.New York, April 19, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaccine Delivery Devices Industry" - https://www.reportlinker.com/p06033211/?utm_source=GNW 3 Billion in the year 2020, is projected to reach a revised size of US$6.5 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Syringes, one of the segments analyzed in the report, is projected to record a 6% CAGR and reach US$5.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Jet Injectors segment is readjusted to a revised 6.5% CAGR for the next 7-year period. - The U.S. Market is Estimated at $1.2 Billion, While China is Forecast to Grow at 9.3% CAGR - The Vaccine Delivery Devices market in the U.S. is estimated at US$1.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 9.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.3% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR. - Other Devices Segment to Record 6.2% CAGR - In the global Other Devices segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$257.1 Million in the year 2020 will reach a projected size of US$378.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$876.4 Million by the year 2027, while Latin America will expand at a 7.5% CAGR through the analysis period. - Select Competitors (Total 42 Featured) - 3MBecton Dickinson & CompanyBioJect Medical Technologies, Inc. (Inovio Pharmaceuticals, Inc.)Corium International, IncGerresheimer AGPharmajet, IncSchott AGValeritasVaxxas Read the full report: https://www.reportlinker.com/p06033211/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Vaccine Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Vaccine Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Vaccine Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Syringes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Syringes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Syringes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Jet Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Jet Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Jet Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Other Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Other Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Other Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Intramuscular Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Intramuscular Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Intramuscular Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Subcutaneous Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Subcutaneous Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Subcutaneous Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Intradermal Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 20: World Historic Review for Intradermal Vaccination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: World 15-Year Perspective for Intradermal Vaccination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 23: World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: World 15-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 25: USA Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: USA Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: USA 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 28: USA Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: USA Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: USA 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 CANADA Table 31: Canada Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Canada Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Canada 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 34: Canada Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Canada Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Canada 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 JAPAN Table 37: Japan Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Japan Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: Japan 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 40: Japan Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: Japan Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: Japan 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 CHINA Table 43: China Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 44: China Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: China 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 46: China Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: China Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: China 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 EUROPE Table 49: Europe Current & Future Analysis for Vaccine Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Vaccine Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Vaccine Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 52: Europe Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: Europe Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: Europe 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 55: Europe Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: Europe Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: Europe 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 FRANCE Table 58: France Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: France Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: France 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 61: France Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: France Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: France 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 GERMANY Table 64: Germany Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Germany Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Germany 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 67: Germany Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Germany Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Germany 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 ITALY Table 70: Italy Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: Italy Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: Italy 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 73: Italy Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: Italy Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: Italy 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 76: UK Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: UK Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: UK 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 79: UK Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: UK Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: UK 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 SPAIN Table 82: Spain Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Spain Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Spain 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 85: Spain Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Spain Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Spain 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 RUSSIA Table 88: Russia Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Russia Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Russia 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 91: Russia Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Russia Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Russia 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 REST OF EUROPE Table 94: Rest of Europe Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 95: Rest of Europe Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Rest of Europe 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 97: Rest of Europe Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Rest of Europe Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Rest of Europe 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 100: Asia-Pacific Current & Future Analysis for Vaccine Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Vaccine Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Vaccine Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 103: Asia-Pacific Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Asia-Pacific Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Asia-Pacific 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 106: Asia-Pacific Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Asia-Pacific Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Asia-Pacific 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 AUSTRALIA Table 109: Australia Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: Australia Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: Australia 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 112: Australia Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: Australia Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: Australia 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 INDIA Table 115: India Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: India Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: India 15-Year Perspective for Vaccine Delivery Devices by Device - Percentage Breakdown of Value Sales for Syringes, Jet Injectors and Other Devices for the Years 2012, 2020 & 2027 Table 118: India Current & Future Analysis for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: India Historic Review for Vaccine Delivery Devices by Route Of Administration - Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: India 15-Year Perspective for Vaccine Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Intramuscular Vaccination, Subcutaneous Vaccination, Intradermal Vaccination and Other Route of Administrations for the Years 2012, 2020 & 2027 SOUTH KOREA Table 121: South Korea Current & Future Analysis for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: South Korea Historic Review for Vaccine Delivery Devices by Device - Syringes, Jet Injectors and Other Devices Markets - Independent Analysis of Annual Sales in US$ Million Please contact our Customer Support Center to get the complete Table of ContentsRead the full report: https://www.reportlinker.com/p06033211/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
We roll along with our top 100 prospects in the 2021 NFL draft with No. 15 overall — a long press corner with great bloodlines and thrilling upside.
MERRITT, B.C. — A wildfire burning near homes in British Columbia's southern interior has prompted the first evacuation alert of B.C.'s barely three-week-old wildfire season. The Thompson-Nicola Regional District issued the alert for the small community of Canford and for homes in a subdivision about 12 kilometres northwest of Merritt. The BC Wildfire Service says the suspected human-caused blaze was fanned by winds after being sparked on Sunday and now covers an estimated one square kilometre. It is one of about a dozen wildfires reported Sunday from southern Vancouver Island to the Prince George and Cranbrook regions. The wildfire danger rating has been ranked at low to moderate for much of the province, but several days of unseasonably warm weather has the potential to rapidly dry undergrowth as snow melts. Environment Canada says record temperatures were set in 11 B.C. communities on Sunday, including a high of 28.4 C in Pemberton, and while conditions in Merritt remain warmer than usual, below freezing temperatures overnight could help crews tame the nearby fire. This report by The Canadian Press was first published April 19, 2021. The Canadian Press
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Nucleic Acid Isolation and Purification Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”LOS ANGELES, April 19, 2021 (GLOBE NEWSWIRE) -- The Global Nucleic Acid Isolation and Purification Market is expected to grow at a CAGR of around 8.8% from 2020 to 2027 and reach the market value of over US$ 7,623.6 Mn by 2027. In 2019, North America held the largest share of the nucleic acid isolation and purification market. The key factors driving the growth of the nucleic acid isolation and purification market in North America are significant R&D spending in biotechnology and pharmaceutical companies, technological advancements, and government support. The Asia Pacific region, on the other hand, is expected to grow at the fastest CAGR during the forecast period. Some of the major factors supporting the growth of the Asia Pacific nucleic acid isolation and purification market are an increase in the number of genomic projects and increased R&D investments by pharmaceutical and biotechnology companies in this region. DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2573 Market Drivers One of the major factors driving the global nucleic acid isolation and purification market is the increasing demand for nucleic acid tests required for pipeline studies of genetic engineering and molecular diagnostics. Furthermore, rising advances in clinical diagnostic techniques increased public-private funding for life science research, and increased automation globally are factors that have a positive impact on the global nucleic acid isolation and purification market. Segmental Outlook The global nucleic acid and purification market is segmented based on product, type, method, application, and end-user. By product, the market is segmented as kits, reagents, and instruments. By type, the market is segmented as plasmid DNA isolation and purification, total RNA isolation and purification, circulating nucleic acid isolation and purification, genomic DNA isolation and purification, messenger RNA isolation and purification, microRNA isolation and purification, PCR cleanup, and other nucleic acid isolation and purification types. By method, the market is segmented as column-based isolation and purification, magnetic bead-based isolation and purification, reagent-based isolation and purification, and other isolation and purification methods. VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/nucleic-acid-isolation-and-purification-market By application, the market is segmented as diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. By end-user, the market is segmented as Hospitals & diagnostic centers, academic & government research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end-users. Competitive Landscape The major players involved in the Nucleic Acid Isolation and Purification market involve QIAGEN, Thermo Fisher Scientific, F. Hoffmann-La Roche AG. Other prominent players involve The Merck Group, Agilent Technologies, Inc., Illumina, Inc., Takara Bio Inc., Promega Corporation, GE Healthcare, Danaher Corporation, New England Biolabs, Bio-Rad Laboratories, Inc., and among others Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports Some of the key observations regarding nucleic acid isolation and purification market include: In April 2020, QIAGEN announced a collaboration with Gilson to provide researchers the ability to limit operator-dependent variation in their manual nucleic acid extraction results and improve the traceability of their workflows. The agreement brings together two influential leaders in the life science industries: Gilson, a global manufacturer of sample preparation technology, and QIAGEN, a leading global provider of molecular diagnostics and sample preparation technologies. This collaboration will integrate Gilson’s TRACKMAN® Connected digital bench tools and QIAGEN’s manual nucleic acid extraction kits to create consistency between collaborators, increase confidence in their execution of extraction protocols, and improve traceability at the bench. In April 2021, Thermo Fisher Scientific announced the launching of a new product, namely "Kingfisher Apex Purification System" a high-throughput sample purification instrument designed for scientists who need to automate the extraction of DNA, RNA, proteins, and cells from an array of sample types. The instrument is easy to use, saves time, and enables consistent results even as laboratory needs evolve.In July 2018, F. Hoffmann-La Roche AG announced a collaboration with PureTech Health plc. The collaboration advance PureTech’s milk-derived exosome platform technology for the oral administration of Roche’s antisense oligonucleotide platform. Under the terms of the agreement, PureTech Health will receive up to $36 million, including upfront payments, research support, and early preclinical milestones. PureTech Health will be eligible to potentially receive development milestone payments of over $1 billion and additional sales milestones and royalties for an undisclosed number of products. INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2573 BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2573 Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 For Latest Update Follow Us: https://twitter.com/AcumenRC https://www.facebook.com/acumenresearchandconsulting https://www.linkedin.com/company/acumen-research-and-consulting
Yahoo Movies